Kairos Pharma, Ltd. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.09 | $-0.06 | +33.3% | Beat |
| Q12026 FY2026 | $-0.07 | $-0.08 | -14.3% | Miss |
| Q42025 FY2025 | — | $-0.07 | — | Miss |
Back to KAPA overview · KAPA holders · KAPA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.